Abstract
BackgroundThe programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) have shown positive efficacy in several solid cancers due to their targeted antitumour effects. However, the frequency and clinical implication value in prostate cancer still remain unclear.MethodsThe PD-1/PD-L1 expression was detected by immunohistochemical (IHC) analysis in 96 retrospectively collected cases of prostatic cancer and 44 controls of benign prostatic hyperplasia (BPH). Its correlation with clinicopathological features including age, PSA level, Gleason score, lymph node metastasis, clinical T stage and risk factor grade in prostate cancer was also assessed.ResultsThe PD-L1-positive expression was significantly higher in cancer cases compared with benign tissues, whereas no difference in PD-1 positive expression was found. Moreover, the PD-L1 expression in tumour cells or lymphocytes was associated with Gleason score, but not related to age, preoperative PSA level, clinical T-stage, lymph node metastasis and grade of risk factors. In addition, no association between the positive expression of PD-1 and PD-L1 in tumour cells and lymphocytes was found.ConclusionsThe expression of PD-L1 not PD-1 is highly prevalent in prostate cancer. PD-L1 is closely related to Gleason score and may be a co-factor associated with the progression of prostate cancer.
Highlights
Prostate cancer has become the second most common malignant cancer among men, with approximately 174, 650 new cases occurred in America [1]
programmed death 1 (PD-1)/ programmed death-ligand 1 (PD-L1) inhibitors combined with androgen receptor antagonists can improve the effect and prognosis of tumour treatment [7,8,9]
Expression of PD-1 and PD-L1 in prostate tissue In total, 96 cases of prostatic carcinoma and 44 controls of prostatic hyperplasia were immunohistochemically stained for PD-1 and PD-L1
Summary
Prostate cancer has become the second most common malignant cancer among men, with approximately 174, 650 new cases occurred in America [1]. Besides surgery, radiotherapy and chemotherapy, immunotherapy involving PD-1/PD-L1 inhibitors has become a new promising treatment in the field of cancer therapy. PD-1/PD-L1 inhibitors can suppress the adaptive immune system and reverse the mechanism of tumour. He et al World Journal of Surgical Oncology (2021) 19:215. Graff et al [8] used PD-1 inhibitors to carry out a phase II clinical trial treatment of castrated resistant prostate cancer (mCRPC). Bishop et al [9] had shown ENZ resistance CRPC is associated with a high frequency of PD-1/L1 therapy targets, in the mouse models, but in patients. The frequency and clinical implication value in prostate cancer still remain unclear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
